AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
EDIT Stock Up 20%: Insider Trading, Hedge Fund Activity and Analyst Ratings
ByAinvest
Monday, Jul 21, 2025 8:04 pm ET1min read
$EDIT stock has risen 20% today, with $8.1mln in trading volume. Insiders have made 6 trades in the past 6 months, with 0 purchases and 6 sales. 60 institutional investors have added shares, while 99 have decreased their positions. Analysts have issued 2 buy ratings and 0 sell ratings, with a median price target of $3.5.
Editas Medicine (EDIT) stock has experienced a significant 20% increase today, with trading volume reaching $8.1 million. The stock's performance has been driven by a number of factors, including insider activity, institutional investment, and analyst ratings.In the past six months, insiders have made a total of 6 trades, with all being sales. This activity indicates a potential bearish sentiment among insiders. However, the stock has seen a net increase in institutional ownership, with 60 investors adding shares and 99 decreasing their positions. This shift suggests a growing interest in the company's prospects.
Analysts have been largely positive about Editas Medicine, with 2 buy ratings and no sell ratings issued in the past month. The median price target stands at $3.5, representing a 13.77% upside from the current price of $2.76. The average price target among analysts is $3.14, with a high forecast of $4.00 and a low forecast of $1.00 [1].
Despite the positive analyst sentiment, Editas Medicine faces significant financial challenges. The company has been operating at a loss, with the previous quarter's earnings per share (EPS) at -$0.92. The next quarter's EPS estimate is -$0.39, with a range of -$0.56 to -$0.29. The company has also been outperforming its industry peers in terms of sales estimates, beating its estimates 50% of the time in the past 12 months [2].
In conclusion, Editas Medicine stock has shown resilience today, with strong institutional buying and positive analyst ratings. However, the company's financial performance remains a concern, with ongoing losses and zero revenue. Investors should closely monitor the company's financials and any new developments in its gene editing technology.
References:
[1] https://www.tipranks.com/stocks/edit/forecast
[2] https://www.tipranks.com/stocks/edit/forecast
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet